MRE11

Across TCGA pan-cancer cohorts, MRE11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRE11 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MRE11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRE11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, ACC, and SCLC are the cancer types where MRE11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	36	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
BRCA	OS	Median	All	0.746	0.924	.010	6	view →
UCEC	OS	Median	III,IV	0.915	0.548	.048	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRE11–KIRC (DFS)

Open the KIRC breakdown →